抗中性粒细胞胞浆抗体血管炎

别名

抗中性粒细胞胞浆抗体相关小血管炎

基本事实

患病率

1-5 / 10 000（Germany）

近两年的全球研究 699L2

2024/08 起在 Europe PMC 检索所得，按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务，尚未引入。

• 2026-08
  Recognition of ear, nose and throat involvement in patients with ANCA-associated vasculitis: from in-depth interviews to insights for the future
  European archives of oto-rhino-laryngology : official journal of the E · DOI · Europe PMC
• 2026-08综述
  Advances in the treatment of eosinophilic granulomatosis with polyangiitis
  Nature reviews. Rheumatology · DOI · Europe PMC
• 2026-08
  Trends in Clinical Indications for Plasma Exchange in Adult Patients Between 2008 and 2024 in Bogotá, Colombia
  Journal of clinical apheresis · DOI · Europe PMC
• 2026-07荟萃分析系统综述综述
  Risk Factors for Pulmonary Involvement in Patients with ANCA-associated Vasculitis: A Systematic Review and Meta-analysis
  Clinical reviews in allergy & immunology · DOI · Europe PMC
• 2026-07综述
  Research progress on the diagnostic value of ANCA in autoimmune diseases of patients with refractory rhinosinusitis
  Immunobiology · DOI · Europe PMC
• 2026-07
  Familial associations between ANCA-associated vasculitis and other immune-mediated inflammatory diseases: a case control study
  Rheumatology international · DOI · Europe PMC
• 2026-07
  Towards a proteomic plasma biomarker panel for diagnosing vasculitis remission
  Nature communications · DOI · Europe PMC
• 2026-07综述病例报告
  The Effect of Teriparatide in a Brown Tumor Patient With Pathological Hip Fracture: A Case Report and Literature Review
  JBJS case connector · DOI · Europe PMC
• 2026-07
  Real-world efficacy and safety of avacopan in ANCA-associated vasculitis: a retrospective comparative study
  RMD open · DOI · Europe PMC
• 2026-07
  Avacopan-Associated Hepatobiliary Adverse Events and Vanishing Bile Duct Syndrome: A PMDA/JADER and FAERS Reporting-Profile Comparison
  Hepatology research : the official journal of the Japan Society of Hep · DOI · Europe PMC
• 2026-07系统综述
  The pharmacokinetics and its covariates of rituximab in different clinical populations: a systematic review and narrative synthesis
  European journal of clinical pharmacology · DOI · Europe PMC
• 2026-07
  Genetic associations of eosinophilic granulomatosis with polyangiitis in the Japanese population: exploring similarities and differences with European populations
  RMD open · DOI · Europe PMC
• 2026-07
  Extracellular vesicles exposing complement split products are associated with kidney involvement in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)
  RMD open · DOI · Europe PMC
• 2026-07病例报告
  [Diffuse bilateral pulmonary infiltrates with multiorgan involvement]
  Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chine · DOI · Europe PMC
• 2026-06综述
  Advances in the Diagnosis, Treatment and Prognosis of ANCA-Associated Glomerulonephritis
  Medicina (Kaunas, Lithuania) · DOI · Europe PMC
• 2026-06病例报告
  Pediatric case of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis with immunoglobulin a deposition diagnosed early through school urinary screening
  CEN case reports · DOI · Europe PMC
• 2026-06综述
  Intensive Care Management of ANCA-associated Vasculitides: a Narrative Review
  Current rheumatology reports · DOI · Europe PMC
• 2026-06
  Anti-neutrophil cytoplasmic antibody associated vasculitis: a retrospective epidemiological study in an Aotearoa New Zealand cohort
  The New Zealand medical journal · DOI · Europe PMC
• 2026-06荟萃分析系统综述综述
  Kidney failure in patients with ANCA-associated vasculitis: A systematic review of outcomes
  Autoimmunity reviews · DOI · Europe PMC
• 2026-06开放获取
  No benefit of adding glucocorticoids to maintenance treatment in reducing the risk of major relapses in ANCA-associated vasculitis: real life data from a longitudinal cohort study
  RMD open · DOI · Europe PMC

境外已获批用于本病的药物 1L2

欧盟 0 项、美国 1 项。同一药物在两地各批一次的，会分别列出。

• Rituxan美国2011-04-19
  rituximab
  官方记录

数据来自欧洲药品管理局（EMA）的药品与孤儿药资格公开导出表，以及美国 FDA 孤儿药资格数据库。两边口径不同：欧盟一侧取的是当前状态仍为「已授权」的药品；美国一侧记录的是「曾获批准」这一事实，FDA 的公开表不追踪药物此后是否退市（例如 Relyvrio 于 2024 年撤市，表中仍记为已获批）。请以官方记录页为准。

在中国开展的临床试验 63L2

按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实，并与主治医生商量。

登记为可入组 42

• 招募中NCT05315141
  Multicenter Cohort Study of AAV in Hunan of China
  观察性 · 2022/03/16Xiangya Hospital of Central South University
  中国研究中心 1 个：Changsha
• 招募中NCT05965284
  Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)
  IV 期 · 干预性 · 2023/03/09Chinese SLE Treatment And Research Group
  中国研究中心 1 个：Beijing
• 仅邀请入组NCT05859997
  Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
  不适用 · 干预性 · 2023/05/17Bioray Laboratories
  中国研究中心 1 个：Shanghai
• 招募中NCT05962840
  Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)
  IV 期 · 干预性 · 2023/06/29Chinese SLE Treatment And Research Group
  中国研究中心 1 个：Beijing
• 招募中NCT06056921
  Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
  I 期 · 干预性 · 2023/08/31Chongqing Precision Biotech Co., Ltd
  中国研究中心 1 个：Taiyuan
• 招募中NCT05979051
  A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）
  II 期、III 期 · 干预性 · 2023/11/16Guangdong Hengrui Pharmaceutical Co., Ltd
  中国研究中心 2 个：Beijing、Hangzhou
• 招募中NCT06277427
  Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells
  不适用 · 干预性 · 2024/02/05Lingli Dong
  中国研究中心 1 个：Wuhan
• 招募中NCT06285279
  The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
  I 期 · 干预性 · 2024/03/04Nanjing University School of Medicine
  中国研究中心 1 个：Nanjing
• 招募中NCT06379646
  An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
  不适用 · 干预性 · 2024/04/24China Immunotech (Beijing) Biotechnology Co., Ltd.
  中国研究中心 1 个：Shanghai
• 尚未开始招募NCT06420154
  The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases
  早期 I 期 · 干预性 · 2024/05/27First Affiliated Hospital of Wenzhou Medical University
  中国研究中心 1 个：Wenzhou
• 招募中NCT06350110
  Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
  I 期、II 期 · 干预性 · 2024/07/10Essen Biotech
  中国研究中心 1 个：Beijing
• 招募中NCT06548607
  Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
  早期 I 期 · 干预性 · 2024/09/14Nanjing Bioheng Biotech Co., Ltd.
  中国研究中心 1 个：Bengbu
• 招募中NCT06794008
  BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
  II 期 · 干预性 · 2024/12/26Peking University People's Hospital
  中国研究中心 1 个：Beijing
• 招募中NCT06775912
  Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases
  早期 I 期 · 干预性 · 2025/01/03Nanjing Bioheng Biotech Co., Ltd.
  中国研究中心 1 个：Lianyungang
• 招募中NCT06614270
  Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
  不适用 · 干预性 · 2025/01/06Second Affiliated Hospital, Zhejiang University, School of Medicine
  中国研究中心 1 个：Hangzhou
• 招募中NCT06941129
  CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
  I 期 · 干预性 · 2025/02/11Institute of Hematology & Blood Diseases Hospital, China
  中国研究中心 1 个：Tianjin
• 尚未开始招募NCT06978738
  UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
  I 期 · 干预性 · 2025/05Changzhou No.2 People's Hospital
  中国研究中心 1 个：Changzhou
• 招募中NCT06978647
  A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
  I 期 · 干预性 · 2025/05/19China Immunotech (Beijing) Biotechnology Co., Ltd.
  中国研究中心 1 个：Beijing
• 招募中NCT06980597
  A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
  I 期 · 干预性 · 2025/06Beijing GoBroad Hospital
  中国研究中心 2 个：Beijing
• 尚未开始招募NCT06986018
  Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV
  早期 I 期 · 干预性 · 2025/06/14Peking University People's Hospital
  中国研究中心 1 个：Beijing
• 招募中NCT06828042
  Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
  I 期、II 期 · 干预性 · 2025/07/01Peking University Third Hospital
  中国研究中心 1 个：Beijing
• 尚未开始招募NCT07033299
  The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis
  I 期 · 干预性 · 2025/07/01Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
  中国研究中心 1 个：Wuhan
• 招募中NCT07203404
  A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
  早期 I 期 · 干预性 · 2025/07/24Nanjing Bioheng Biotech Co., Ltd.
  中国研究中心 1 个：Shanghai
• 招募中NCT07104721
  A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
  I 期 · 干预性 · 2025/08/04China Immunotech (Beijing) Biotechnology Co., Ltd.
  中国研究中心 1 个：Hefei
• 招募中NCT07123519
  A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
  I 期 · 干预性 · 2025/08/13China Immunotech (Beijing) Biotechnology Co., Ltd.
  中国研究中心 1 个：Tianjin

另有 17 项未列出。

中国境外的在招试验 95L2

CT.gov 报告命中 95 项，此处取回并展示最近的 15 项。

• 尚未开始招募NCT07636655
  Immune Monitoring Following B-cell Depletion in ANCA-associated Vasculitis
  观察性 · 2026/09/01Nantes University Hospital
  法国
• 尚未开始招募NCT07737470
  Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research
  观察性 · 2026/09/01Assistance Publique - Hôpitaux de Paris
• 招募中NCT07556484
  Pharmacokinetics Of Emulsified Avacopan Applied By NG Tube
  I 期 · 干预性 · 2026/08/01Mayo Clinic
  美国
• 尚未开始招募NCT07746180
  Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis
  II 期 · 干预性 · 2026/07/31Chinese PLA General Hospital
• 招募中NCT07388277
  CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis
  I 期、II 期 · 干预性 · 2026/07/09Marcela V. Maus, M.D.,Ph.D.
  美国
• 尚未开始招募NCT07490275
  Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases
  I 期 · 干预性 · 2026/07/01Institute of Hematology & Blood Diseases Hospital, China
• 尚未开始招募NCT07176546
  TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
  II 期、III 期 · 干预性 · 2026/07Robert Spiera, MD
  美国
• 尚未开始招募NCT06226662
  Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)
  II 期 · 干预性 · 2026/06NovelMed Therapeutics
• 尚未开始招募NCT07444567
  Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
  III 期 · 干预性 · 2026/05/25AstraZeneca
• 招募中NCT07087912
  Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
  IV 期 · 干预性 · 2026/03/16University of Sao Paulo General Hospital
  巴西
• 尚未开始招募NCT07373262
  Avacopan Added to Standard-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney Involvement
  III 期 · 干预性 · 2026/03/01University Hospital, Toulouse
  法国
• 尚未开始招募NCT07451847
  Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis.
  IV 期 · 干预性 · 2026/02Assistance Publique - Hôpitaux de Paris
  法国
• 招募中NCT07258524
  PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated Vasculitis
  观察性 · 2026/01/28University of Edinburgh
  英国
• 招募中NCT07089121
  Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
  I 期、II 期 · 干预性 · 2026/01/14Cartesian Therapeutics
  美国
• 尚未开始招募NCT07251179
  Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies
  观察性 · 2026/01/01University Hospital, Strasbourg, France
  法国

外部标识与链接